Preferences help
enabled [disable] Abstract
Number of results
2005 | 52 | 3 | 601-607
Article title

Use of cell therapy as a means of targeting chemotherapy to inoperable pancreatic cancer

Title variants
Languages of publication
Although approved for the treatment of pancreatic cancer, the chemotherapeutic agent ifosfamide is not an effective therapy for this type of tumour. Ifosfamide must be activated by cytochrome P450 (P450) enzymes in the liver, initially to a short lived intermediate and then to toxic metabolites that are subsequently distributed by the circulatory system. Particularly for pancreatic cancer, this liver-mediated conversion results in relatively high systemic toxicities and poor therapeutic concentrations at the liver-distant site of the tumour. Activation of ifosfamide at the site of the tumour may allow lower doses to be used, while increasing the therapeutic index due to the resultant active concentrations generated locally. A cell-based therapy has been conceived where encapsulated, 293-derived cells genetically modified to overexpress a cytochrome P450 enzyme, are implanted near solid tumours. The cells are encapsulated in polymers of cellulose sulphate in order to provide a means of immunoprotection in vivo as well as to physically constrain them to the vicinity of the tumour. A major advantage of this strategy is that it allows one standard cell line to be applied to all patients and this approach can be extended to the treatment of other tumour types. After proof of principle studies in animal models, a phase I/II clinical trial was initiated in patients with stage III/IV nonresectable pancreatic cancer. Encapsulated cells were angiographically placed into the tumour vasculature of 14 patients and followed by systemic low dose ifosfamide treatment. Angiographic delivery of encapsulated cells proved feasible in all but one patient, and was well tolerated with no capsule or ifosfamide treatment-related adverse events. Four of the treated patients showed tumour regressions after capsule delivery and ifosfamide treatment in computer-tomography scans. The other 10 patients showed no further tumour growth (i.e. stable disease) during 20 weeks observation period. The median life expectancy of the patient collective was extended two fold as compared to age and status matched historical controls, with a 3-fold improvement in one year survival being attained. Evidence for a clinical benefit of the treatment was also obtained on the basis of standard parameters for quality of life. This approach has been evaluated by the European Medicines Evaluation Agency (EMEA) and orphan drug status has been granted. A pivotal clinical trial is now being planned with the help of the EMEA. Taken together, the data from this clinical trial suggest that encapsulated cytochrome P450-expressing cells combined with chemotherapy may be useful for the local treatment of a number of solid tumours and support the performance of further clinical studies of this new treatment.
Physical description
  • Research Institute for Virology and Biomedicine, University of Veterinary Medicine, Vienna, Austria
  • Austrianova Biotechnology GmbH, Vienna, Austria
  • Ajani JA, Abbruzzese JL, Goudeau P, Faintuch JS, Yeomans AC, Boman BM, Nicaise C, Levin B (1988) Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. J Clin Oncol 6: 1703-1707.
  • Block A, Chen SH, Kosai K, Finegold M, Woo SL (1997) Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: regression of hepatic metastasis of pancreatic tumors. Pancreas 15: 25-34.
  • Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, von Hoof DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol 15: 2403-2413.
  • Carmichael J, Fink U, Russell RCG, Spittle MF, Harris AL, Spiessi G, Blatter J (1996) Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73: 101-105.
  • Carrio M, Romagosa A, Mercade E, Mazo A, Nadal M, Gomez-Foix A-M, Fillat, C (1999) Enhanced pancreatic tumor regression by a combination of adenovirus and retrovirus-mediated delivery of the herpes simplex virus thymidine kinase gene. Gene Ther 6: 547-553.
  • Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG (1994) Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12: 29-34.
  • Cerny T, Martinelli G, Goldhirsch A, Terrier F, Joss R, Fey MF, Brunner KW, Kupfer A (1991) Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study. J Cancer Res Clin Oncol 117: S135-S138.
  • Chen L, Waxman DJ (1995) Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res 55: 581-589.
  • Dautzenberg H, Schuldt U, Grasnick G, Karle P, Müller P, Löhr M, Pelegrin M, Piechaczyk M, von Rombs K, Günzburg WH, Salmons B, Saller RM (1999) Development of cellulose sulphate based polyelectrolyte complex microcapsules for medical applications. Ann NY Acad Sci 875: 46-63.
  • Diaz-Rubio E (2004) New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. Oncologist 9: 282-294.
  • Dondelinger R (1999) Advances in abdominal interventional radiology. Lancet 353: SI15-SI18.
  • Gad-el-Mawla N (1986) Ifosfamide in advanced pancreatic cancer. A 5-year experience. Cancer Chemother Pharmacol 18 (Suppl 2): 55-56.
  • Gad-el-Mawla N, Ziegler JL (1981) Ifosfamide treatment of pancreatic cancer. Cancer Treat Rep 65: 357-358.
  • Günzburg WH, Lohr M, Salmons B (2002) Novel treatments and therapies in development for pancreatic cancer. Expert Opin Investig Drugs 11: 769-786.
  • Haack K, Linnebacher M, Eisold S, Zoller M, von Knebel Doeberitz M, Gebert J (2000) Induction of protective immunity against syngeneic rat cancer cells by expression of the cytosine deaminase suicide gene. Cancer Gene Ther 7: 1357-1364.
  • Hauser O, Prieschl-Grassauer E, Salmons B (2004) Encapsulated, genetically modified cells producing in vivo therapeutics. Curr Opin Mol Ther 6: 412-420.
  • Hlavaty J, Portsmouth D, Stracke A, Salmons B, Günzburg WH, Renner M (2004a) Effects of sequences of prokaryotic origin on titre and transgene expression in retroviral vectors.
  • Hlavaty J, Stracke A, Klein D, Salmons B, Günzburg WH, Renner M (2004b) Multiple modifications allow high titer, tissue-specific retroviral vector production. J Virol 78: 1384-1392.
  • Howard BD, Boenicke L, Scniewind B, Henne-Bruns D, Kalthoff H (2000) Transduction of human pancreatic tumor cells with vesicular stomatitis virus G-pseudotyped retroviral vectors containing a herpes simplex virus thymidine kinase mutant gene enhances bystander effects and sensitivity to ganciclovir. Cancer Gene Ther 7: 927-938.
  • Kammertöns T, Gelbmann W, Karle P, Saller R, Salmons B, Günzburg WH, Uckert W (2000) Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine. Cancer Gene Ther 7: 629-636.
  • Kanyama H, Tomita N, Yamano T, Aihara T, Miyoshi Y, Ohue M, Sekimoto M, Sakita I, Tamaki Y, Kaneda Y, Senter PD, Monden M (2001) Usefulness of repeated direct intratumoral gene transfer using hemagglutinating virus of Japan-liposome method for cytosine deaminase suicide gene therapy. Cancer Res 61: 14-18.
  • Karle P, Müller P, Renz R, Jesnowski R, Saller RM, von Rombs K, Nizze H, Liebe S, Günzburg WH, Salmons B, Löhr M (1998) Intratumour injection of encapsulated cells producing an ifosfamide activating cytochrome P450 for targeted chemotherapy. Adv Exp Med Biol 451: 97-106.
  • Karle P, Renner M, Salmons B, Günzburg WH (2001) Necrotic, rather than apoptotic, cell death caused by cytochrome P450 activated ifosfamide. Cancer Gene Ther 8: 220-230.
  • Keizer HJ, Ouwerkerk J, Welvaart K, van der Velde CJH, Cleton FJ (1995) Ifosfamide treatment as a 10-day continuous intravenous infusion. J Cancer Res Clin Oncol 121: 297-302.
  • Kröger JC, Bergmeister H, Hoffmeyer A, Ceijna M, Karle P, Saller R, Schwendenwein I, von Rombs K, Liebe S, Günzburg WH, Salmons B, Hauenstein K-H, Losert U, Löhr M (1999) Intra-arterial instillation of microencapsulated cells in the pancreatic arteries in pig. Ann NY Acad Sci 880: 374-378.
  • Kurowski V, Wagner T (1993) Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 33: 36-42.
  • Loehrer PJ, Williams SD, Einhorn LH, Ansari R (1985) Ifosfamide: an active drug in the treatment of adenocarcinoma of the pancreas. J Clin Oncol 3: 367-372.
  • Löhr M, Müller P, Karle P, Stange J, Mitzner S, Jesnowski R, Nizze H, Nebe B, Liebe S, Salmons B, Günzburg WH (1998) Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450. Gene Therapy 5: 1070-1078.
  • Löhr JM, Bago ZT, Bergmeister H, Ceijnka M, Freund M, Gelbmann W, Günzburg WH, Jesnowski R, Hain J, Hauenstein K, Henninger W, Hoffmeyer A, Karle P, Kröger J-C, Kundt G, Liebe S, Losert U, Müller P, Probst A, Püschel K, Renner M, Renz R, Saller R, Salmons B, Schuh M, Schwendenwein I, von Rombs K, Wagner T, Walter I (1999) Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced stage pancreatic carcinoma: a phase I/II study. J Mol Med 77: 393-398.
  • Lohr M, Hoffmeyer A, Kroger J-C, Freund M, Hain J, Holle A, Karle P, Knofel WT, Liebe S, Muller P, Nizze H, Renner M, Saller RM, Wagner T, Hauenstein K, Gunzburg WH, Salmons B (2001) Microencapsulated, cellmediated treatment of inoperable pancreatic carcinoma. Lancet 357: 1591-1592.
  • Löhr M, Saller RM, Salmons B, Gunzburg WH (2002) Microencapsulation of genetically engineered cells for cancer therapy. Methods Enzymol 346: 603-618.
  • Löhr JM, Kröger J-C, Hoffmeyer A, Benz S, Müller P, Saller R, Nizze H, Klöppel G, Bergmeister H, Bago Z, Günzburg WH, Karle P, Obermaier R, Probst A, Renner M, Salmons B, Schwendenwein I, von Rombs K, Wiessner R, Losert U, Wagner T, Hauenstein K (2003) Intra-arterial instillation of microencapsulated, ifosfamide activating cells in the pig pancreas for chemotherapeutic targeting. Pancreatology 3: 55-63.
  • Lohr M, Hoffmeyer A, Kroger J-C, Freund M, Gunzburg WH, Hain J, Holle A, Knofel WT, Liebe S, Muller P, Nizze H, Renner M, Saller RM, Salmons B, Wagner T, Hauenstein K (2003) Safety, feasibility and clinical benefit of localized chemotherapy using microencapsulated cells for inoperable pancreatic carcinoma in a phase I/II trial. Cancer Therapy 1: 121-131.
  • Makinen K, Loimas S, Wahlfors J, Alhava E, Janne J (2000) Evaluation of herpes simplex thymidine kinase mediated gene therapy in experimental pancreatic cancer. J Gene Med 2: 361-367.
  • McKeown SR, Ward C, Robson T (2004) Gene-directed enzyme prodrug therapy: a current assessment. Curr Opin Mol Ther 6: 421-435.
  • Rieger J, Durka S, Streffer J, Dichgans J, Weller M (1999) Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, Bcl-2 and dexamethasone. Eur J Pharmacol 365: 301-308.
  • Saller RM, Indraccolo S, Coppola V, Esposito G, Stange J, Mitzner S, Heinzmann U, Amadori A, Salmons B, Gunzburg WH (2002) Encapsulated cells producing retroviral vectors for in vivo gene transfer. J Gene Med 4: 150-160.
  • Salmons B, Gunzburg WH (1993) Targeting of retroviral vectors for gene therapy. Human Gene Therapy 4: 129-141.
  • Shiau A-L, Yang H-M, Wu P, Wu C-L (1998) Provision of postive and negative selections in retroviral vectors containing the cytosine deaminase gene. Gene Therapy 5: 1571-1574.
  • Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R (1999) An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 85: 1261-1268.
  • Talamonti M, Tellez C, Benson A (1998) Local-regional therapy for metastatic liver tumors. Cancer Treat Res. 98: 172-199.
  • Trinchet JC (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332: 1256-1261.
  • Uckert W, Salmons B, Beltinger C, Günzburg WH, Kammertöns T (2003) Combination suicide gene therapy. Methods Mol Med 90: 345-352.
  • Wei MX, Tamiya T, Chase M, Boviatsis EJ, Chang TKH, Kowall NW, Hochberg FH, Waxman DJ, Breakefield XO, Chiocca EA (1994) Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Human Gene Therapy 5: 969-978.
  • Wils JA, Kok T, Wagener DJT, Francois E, Selleslags J, Duez N (1993) Phase II trial with ifosfamide in pancreatic cancer. Eur J Cancer 29A: 290.
  • Zheng X, Johansson M, Karlsson A (2000) Retroviral transduction of cancer cell lines with the gene encoding Drosophila melanogaster multisubstrate deoxyribonucleoside kinase. J Biol Chem 275: 39125-39129.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.